Patients with rheumatoid arthritis (RA) and autoantibodies, such as rheumatoid factor and those against cyclic citrullinated peptides, are designated as seropositive and have a more severe disease with worse prognosis than seronegative RA patients. Understanding the factors that participate in systemic inflammation, in addition to articular commitment, would allow better treatment approaches for prevention of RA comorbidities and disease reactivation. We evaluated whether monocyte subsets and extracellular vesicles (EVs) could contribute to this phenomenon. Seropositive patients had higher levels of proinflammatory cytokines than those of seronegative patients and healthy controls (HCs); however, this systemic inflammatory profile was unrelated to disease activity. High frequencies of circulating EVs positive for IgG, IgM, CD41a, and citrulline, together with altered counts and receptor expression of intermediate monocytes, were associated with systemic inflammation in seropositive patients; these alterations were not observed in seronegative patients, which seem to be more similar to HCs. Additionally, the EVs from seropositive patients were able to activate mononuclear phagocytes in vitro, and induced proinflammatory cytokines that were comparable to the inflammatory response observed at the systemic level in seropositive RA patients; therefore, all of these factors may contribute to the greater disease severity that has been described in these patients.
Rheumatoid arthritis (RA) is characterized by a systemic inflammatory state that mainly affects joints but also other organs, such as skin, eyes, lung, and the cardiovascular system1. Two groups of patients with RA are clearly differentiated: the seropositive and seronegative type. Rheumatoid factor (RF), and antibodies against cyclic citrullinated peptides (anti-CCP) are hallmarks of patients with seropositive RA2. The presence of anti-CCP in patients with seropositive RA has been associated with more persistent inflammation, greater erosive joint damage, more severe clinical manifestations and worse prognosis than those in patients with seronegative RA3. The participation of RF in the disease’s development is not clear yet; however, it is proposed that this autoantibody potentiates the pathological effects of anti-CCP4. After antigen recognition by these autoantibodies, the immune complexes (ICs) formed can activate mononuclear phagocytes in circulation and joints, promoting the secretion of inflammatory mediators, such as TNF-α, IL-6, and IL-1β5. These cytokines are biomarkers of systemic inflammation in RA and contribute to the immunopathology of this disease because their blocking is associated with clinical improvement and remission6,7,8.
The understanding of which circulating factors contribute to the systemic inflammation in RA is essential to find more promising alternatives for the intervention and treatment of these patients. A high number of extracellular vesicles (EVs) have been detected in circulation and synovial fluid of RA patients9,10. The role of EVs in the pathogenesis of RA has begun to be elucidated; for example, these vesicles express autoantigens, such as citrullinated peptides (CPs), form ICs, and participate in the delivery of miRNA, and fibroblast-like synoviocytes activation11. EVs contribute in cell-to-cell communication and have a broad spectrum of effects on immune responses, mainly on monocytes and macrophages, and induce TNF-α, IL-6, and IL-1β production11,12.
Different cell components are involved in the development of inflammation, including neutrophils, mastocytes, T and B lymphocytes, and monocytes/macrophages. Activation of these cells leads to the production of cytokines and mediators responsible for inflammation. More specifically, monocytes/macrophages have been found to be activated in RA13,14,15, to massively infiltrate synovial membranes in RA16,17, and to produce TNF-α17. It has been shown in RA patients that circulating EVs forming ICs (EV-ICs)10,18 induce leukotriene production by neutrophils in vitro, which indicates that these vesicles may contribute to the inflammatory process. We propose that EVs can activate monocytes in circulation and contribute to the systemic inflammatory process in RA, similar to that observed in other systemic autoimmune diseases19. However, the effect of EVs on monocytes has not been previously associated with RA. Therefore, we evaluated whether patients with seropositive RA had any particular profile of circulating EVs and monocytes that could be associated with their systemic inflammatory response and assessed the direct effect of EVs and EV-ICs in mononuclear phagocytes.
Systemic inflammatory response in seropositive patients is characterized by high serum levels of TNF-α, IL-6, and IL-1β
Alterations in serum cytokine levels have been described in different systemic inflammatory processes. Serum cytokines were measured as indicators of the systemic inflammatory state of RA patients. As shown in Fig. 1A, the classification of patients according to disease activity by disease activity score (DAS)−28 showed great variability in cytokine concentrations; patients classified under remission or low activity had either elevated or very low serum concentrations of cytokines. However, when patients were classified according to seropositivity, the groups of anti-CCP+RF+/− and anti-CCPhiRFhi (seropositive) patients had significantly elevated levels of TNF-α, IL-6, IL12p70, and IL-1β, but not IL-8, relative to those in healthy controls (HCs); anti-CCP−RF− (seronegative) patients did not show such increases (Fig. 1A). Interestingly, when we evaluated the cytokines levels in patients with other systemic autoimmune disease (SADs), such as systemic lupus erythematosus (SLE), we did not find differences in proinflammatory cytokines serum concentrations compared with HCs (Data not shown). These findings indicate that serum cytokine concentrations are not increased in all SADs and may be characteristic of seropositive RA patients (anti-CCP+RF+/− and anti-CCPhiRFhi).
A principal component analysis (PCA) was performed to define associations among serum cytokines (IL-1β, IL-12p70, IL-6, TNF-α, and IL-10), C-reactive protein (CRP), and DAS28 variables in patients with seropositive and seronegative RA and HCs (Fig. 1B). The PCA showed two components that explained the 65% of the variability and enabled separation of the variables between the two groups: a group associated with the proinflammatory cytokines that included most of the seropositive patients and a group associated with CRP, IL-10, and the DAS28 that was not clearly associated with seropositivity/seronegativity. HCs and anti-CCP−RF− patients were not defined on the basis of these variables in either group and remained together. With the eigenvalues obtained from the PCA of each variable, a heat map was created. The heat map showed that the cytokines IL-1β, IL-12p70, TNF-α, and IL-6 defined seropositive patients better than did the DAS28 and CRP (Fig. 1B).
High counts of intermediate monocytes in patients with seropositive RA
Alterations in the frequency of circulating monocyte subsets20 and activation of total monocytes producing proinflammatory cytokines13,14,15 have been described in patients with RA. Therefore, we evaluated if the number, frequency, and phenotype of monocyte subsets were associated with seropositivity of patients with RA. A decrease in the proportion of classical monocytes was observed in anti-CCPhiRFhi patients, which was not reflected in absolute counts (Fig. 2A,B). The intermediate monocytes were significantly elevated in both proportion and counts in the seropositive patients relative to HCs. Additionally, the non-classical monocytes were reduced in both the proportion and number in anti-CCPhiRFhi patients (Fig. 2A,B). The expressions of receptors associated with the recognition of EVs and migration of monocyte subsets were evaluated in intermediate monocytes because these cells were the most affected in count and frequency in seropositive patients. Low expressions of HLA-DR and CX3CR1 in seropositive patients, and low expressions of CD86, CD36, CCR2, and CCR5 in anti-CCPhiRFhi patients were observed compared with HCs (Fig. 2C). Low expression of CD18 was found in all monocyte subsets in seronegative patients relative to that in anti-CCPhiRFhi patients and HCs (data not shown).
EVs of seropositive patients are platelet-derived, CPs+, and form ICs
Recent reports indicate that EVs have a pivotal role in autoimmune diseases21,22 because of different pleiotropic effects on mononuclear phagocytes and other components of the immune system21. All patients with RA seem to display elevated EV counts; however, only anti-CCP+RF+/− patients showed a significant difference compared with HCs (Fig. 3A). Regarding EV-size distribution, anti-CCP−RF− and anti-CCP+RF+/− patients had significantly decreased proportions of 0.1–1.0-µm EVs and elevated proportions of 1–3.0-µm and 3–6.0-µm EVs (Fig. 3A,B). The EV phenotype was also studied to identify the cellular source. The seropositive patients had elevated proportions of EV-CD41a+, and the anti-CCP−RF− group had elevated EV-CD105+ relative to that of the anti-CCPhiRFhi patients (Fig. 3C). Taking into account that approximately 50% of the EVs were derived from leukocytes (EV-CD45+), we evaluated different leukocyte sources. All groups of patients had elevated frequencies of EV-HLA-DR+, and the frequency of EV-CD14+ appeared to be decreased, but the difference was statistically significant only in the anti-CCP+RF+/− group (Fig. 3C).
In addition to EV cell sources, components of EVs involved in the RA physiopathology were evaluated. The EV-ICs (IgG + IgM-, IgG-IgM+, and IgG + IgM+) and EV-CPs+ were significantly elevated in seropositive patients relative to those in HCs. The anti-CCP+RF+/− patients had higher frequencies of EV-C1q+ and EV-High-mobility group box 1 (HMGB1)+ than those in the other groups; the EVs of seronegative patients were similar to those of HCs (Fig. 3D). The cell sources of EV-ICs, EV-CPs+, EV-C1q+, and EV-HMGB1+ were both leukocytes and platelets in total patients with RA; however, platelets were the main source in seropositive patients (data not shown). To illustrate the variations in ICs content of the EVs, 5 representative individuals of each group of patients with RA and HCs were randomly selected and a t-Distributed Stochastic Neighbor Embedding (t-SNE) analysis was performed. As expected, it was observed that vesicles from patients with seropositive RA had higher frequencies and a wider distribution of EV-IgM+ and EV-IgG+ than those of HCs and seronegative patients (Fig. 3E).
EVs and monocyte subsets from synovial fluid and circulation share some characteristics
To evaluate whether the phenotype of EVs and monocyte subsets observed in circulation of seropositive patients also can be found in the synovial fluid (SF) of these patients, the SF of one anti-CCP+RF+/− and two anti-CCPhiRFhi patients were assessed. Approximately 20% of the SF infiltrating cells corresponded to monocytes, and strikingly, 70% of these cells corresponded to intermediate monocytes (Fig. 4A). However, there was a greater expression per cell of HLA-DR, CD86, CCR2, CX3CR1, CCR5, and CD32 but lower expression per cell of CD36, CD11b, and FcμR in intermediate monocytes of SF than those in circulating cells of the same patients (Fig. 4B and data not shown). Interestingly, mononuclear phagocytes from patients with seropositive RA of a 24 h culture showed higher expression of CD32 and lesser expressions of CD11b, CD36, and FcμR than those in HCs (Supplementary Figure 1–S1). Then, the phagocytes observed in the SF of patients could acquire this phenotype once they begin their process of tissue differentiation23.
Regarding EVs of SF and similar to circulating EVs, platelets and leukocytes were the main sources of these vesicles; also, the EVs of greater size (FSC-A) and complexity (SSC-A) were those that mainly form ICs in SF; these EVs also contain HMGB1, HLA-DR, and CP in different proportions (Fig. 4C).
EVs, intermediate monocytes, and proinflammatory cytokines allow the discrimination of patients with RA according to seropositivity
To establish which of the variables evaluated in monocyte subsets and EVs from blood are associated with autoantibody levels and systemic inflammation in RA patients, a discriminant analysis was performed with samples of patients and HCs. Twenty-three predictor variables that included intermediate monocyte counts and receptors (CD16, CD64, CD32, CD86, HLA-DR, CCR2, CCR5, CX3CR1), CD18 of three monocyte subsets, cytokines (IL-6, IL1β, and TNF-α), and frequencies of EVs positive for IgG, IgM, HMGB1, CPs, CD41a, and HLA-DR were included. The four study groups were significantly discriminated by these variables (p < 0.05), with a confidence level of 95%. However, anti-CCPhiRFhi and anti-CCP+RF+/− patients showed slight overlap. Interestingly, although HCs and anti-CCP−RF− segregated to the same side, they were mutually excluded (Fig. 5A), which suggested that EVs and intermediate monocytes are closely associated with the systemic inflammation observed in seropositive patients.
EVs from seropositive patients induce proinflammatory cytokine production by mononuclear phagocytes
To evaluate whether EVs from seropositive patients induce production of the cytokines related to the systemic inflammation detected in seropositive patients, we first evaluated the binding and internalization of these vesicles. Intermediate monocytes and mononuclear phagocytes of a 24 h culture from RA patients bound and internalized higher levels of EV-ICs than those of un-opsonized EVs (Fig. 5B). Finally, we found that in response to EVs, mainly EV-ICs, there were accumulations of IL-1β, IL-6, and TNF-α in the supernatants of mononuclear phagocytes of RA patients and HCs (Fig. 5C), which suggested that mononuclear phagocytes, after their EVs interaction, could contribute to the systemic inflammation observed in seropositive patients.
Multiple studies have identified several circulating cytokines and chemokines that reflect the systemic inflammation in RA24,25. However, little is known about the components responsible for this. We observed that higher levels of the serum cytokines IL-1β, IL-12p70, IL-6, and TNF-α were characteristic of patients with seropositive RA; in contrast, seronegative and SADs patients did not have elevated levels of these cytokines. The seropositive patients also exhibited high frequencies of circulating EVs positive for CD41a, IgG, IgM, and CPs, and altered counts, frequencies, and receptor expressions of monocyte subsets, mainly intermediate ones. These changes were not observed in seronegative patients, who more closely resembled HCs. Actually, EV-ICs from seropositive patients, more than EVs, induced the production of IL-1β, IL-6, and TNF-α by mononuclear phagocytes of RA patients and HCs in vitro. No one of the alterations observed in intermediate monocytes and EVs from RA patients were associated with disease activity evaluated by DAS28 (Figure S2 and data not shown). Therefore, these results together with the discriminant analysis suggest that in RA, the seropositive patients are those who mainly present systemic inflammation, which seems to be partially explained by the effect of EVs on mononuclear phagocytes. It is currently believed that seropositive and seronegative are two different RA entities, each with its own pathogenesis, disease course, and genes involved26. Our results agree with this hypothesis because seropositive patients, who have more severe disease and worse outcomes27, exhibited evident systemic inflammation.
Different circulating components, such as cytokines, EVs, and monocyte subsets, were identified according to the seropositivity status of RA patients. A few studies have analyzed IL-17, IL-1528, and IL-3329 cytokines according to anti-CCP positivity. Other studies have focused on evaluating cytokines in SF; Gómez-Puerta et al. in 20133 found higher levels of cytokines IL-1β, IL-10, and IL-17 and the CCL20 chemokine in anti-CCP+ patients than those in seronegative patients. However, it was not clear if there was an association between the local and systemic inflammation process in those patients. Recent evidence has suggested the essential role of cytokines in anti-citrullinated protein antibody (ACPA)-positive patients with RA. It has been observed that the levels of IL-6, IL-17, and IL-8 were significantly elevated in SF from synovial ACPA-positive patients, and that the levels of IL-8 positively correlated with neutrophil counts and worse clinical manifestations in patients with RA30. Another study showed that exposure of osteoclast to ACPAs leads to a preferential release of IL-8, which mediates an autocrine activation of these cells31. Although we did not find significant differences in the serum levels of IL-8 among seropositive patients versus HCs and seronegative patients, it is important to note that we evaluated the serum and not SF concentrations of this cytokine. Therefore, it is possible that IL-8 participates in joint rather than in systemic inflammation. Additionally, it is noteworthy that IL-8 has been more often related to the initial hit of autoantibodies in RA, wherein this cytokine seems to be associated with the induction of initial bone resorption and with higher neuropathic pain than with pannus formation and inflammatory pain32,33.
Our results suggest that systemic inflammatory process does not always coincide with articular inflammation, as shown by the weak association between circulating cytokines and DAS28. This suggest that classifying the disease as active based only on the articular commitment of DAS282 is insufficient to determine individuals with systemic and non-joint inflammation. In addition, we observed that not all patients with high DAS28 exhibited high levels of circulating inflammatory cytokines. This could be party explained by the generation of articular pain unrelated to a systemic inflammatory process because the joints’ sensory neurons can trigger pain in RA in the absence of local inflammation, tissue damage, or infection34. Additionally, irreversible destructive joint lesions often developed in the course of RA, remaining tender even after the inflammatory process subsides. Therefore, DAS28 is an objective score that may lead to an overestimation of disease activity because it could be significantly affected by the parameter of tender joint count. Clinically evaluating patients with RA based only in DAS28 may therefore lead to an inaccurate reflection of the total disease activity (articular and systemic).
Previously, it has been shown that in vitro, EV-ICs caused marked upregulation of leukotriene-B4 production by neutrophils10; however, several studies have shown that monocyte/macrophage are the major source of proinflammatory cytokines and chemokines in the inflamed RA joints, including TNF-α and IL-1β35. Here we observed that EVs, particularly EV-ICs from RA patients, induced IL-6, IL-1β, and TNF-α production by mononuclear phagocytes from HCs and RA patients. Although the inflammatory process in the joints could contribute to circulating cytokines36, our data suggest that other circulating sources of these mediators seem to exist in seropositive patients; particularly, our data support that EV-ICs and their interaction with monocytes could be contributing to this phenomenon. However, it is still matter of investigation whether or not monocytes are the main source of proinflammatory cytokines in seropositive patients at the circulation level.
Circulating cytokines and altered EVs are in a position to affect the function of distant tissues, including adipose, skeletal muscle, liver, and vascular endothelium37,38. It has been shown that chronic elevation in cytokine levels, irrespective of magnitude or cause, can generate a spectrum of proatherogenic changes that include insulin resistance, dyslipidemia, prothrombotic effects, pro-oxidative stress, and endothelial dysfunction in RA patients25. The ability to define the systemic inflammation in these patients could allow better establishment of the type and dose of the treatment to prevent comorbidities associated with seropositive RA and/or avoid disease reactivation. Therefore, the evaluation of serum cytokines, as well as some variables found in EVs and monocytes, could be a promising tool for follow-up of patients. Additionally, the identification of systemic inflammation in RA patients at the remission state defined by DAS28, could provide significant insights into the pathogenesis of RA and could be used to guide the initiation of disease modifying drugs in these patients.
In agreement with previous studies9,10, we found that platelets constitute the most frequent source of EVs in patients with RA; in addition, our study showed that this occurs mainly in seropositive patients. Furthermore, these patients had the highest frequencies of circulating EV-ICs+ and EV-CPs+, which indicates that these structures are an important source of ICs, autoantigens, and DAMPs in the circulation and SF of patients with RA, as previously proposed by others10,18,21,22. Depletion of platelets, in a deficient collagen receptor glycoprotein-(GP)VIa mouse model of RA, attenuated inflammatory arthritis, produced lower numbers of platelets-derived EVs in vivo, with minor ankle thickness and poor bone and cartilage erosion relative to those in control mice9, which suggested that these platelet-derived vesicles have an important role in the pathogenesis of arthritis.
In anti-CCP+RF+/− patients versus HCs a significant decrease in EV-CD14+ was observed. CD14 can be found in two forms; a form anchored to the membrane by a glycosylphosphatidylinositol tail (mCD14) and a soluble form (sCD14)39. It has been described that under inflammatory conditions, CD14 can be released from monocytes membrane into the culture milieu40. Therefore, the decrease frequency of this molecule observed in EVs from seropositive patients with RA could be based on the aforementioned phenomenon. In fact, an increase in the sCD14 blood level in patients with RA has been reported41. Moreover, an increase in the frequency of EV-HLA-DR+ was observed in all groups of patients with RA, together with high frequencies of platelet-derived EVs. Although the expression of HLA-DR in platelets or platelets-derived EVs has not been observed in healthy individuals, it has been described previously in platelets of patients with autoimmune diseases such as acute idiopathic thrombocytopenic purpura42. A study with similar patients showed that platelets-derived EVs also have HLA-DR expression43. Thus, the increase in EV-HLA-DR+ in patients with RA can either be related to an increased expression of HLA-DR+ in EV-CD41a+ or could correspond to a leukocyte source. Further experiments are required to solve these assumptions in patients with RA.
Similar to our results, Nathalie Cloutier et al.10 reported that circulating and SF EVs from patients with RA are highly heterogeneous in size and larger than those from HCs. However, according the t-SNE diagrams, no clear association was observed between the EV-size increase and the formation of ICs in seropositive patients with RA. In this respect, it is important to mention that we did not exclude EV aggregation, as previously reported44. Actually, it is striking that seropositive patients with RA have lower EVs count than seronegative ones. Although we do not have a clear explanation for this finding, we think it is possible that the formation of ICs by these vesicles can cause these structures to aggregate44,45,46; ICs activate and induce platelet aggregation47, and a considerable frequency of platelets-derived EVs in blood of patients with RA are CD62P+ and CD40L+ (platelet activation markers) (Villar-Vesga J, et al. Submitted manuscript). Therefore, whether ICs can promote aggregation of EVs in a manner similar to platelets remains unknown. Additional studies are required to corroborate this hypothesis. Previously, it was verified that EVs from the SF of RA patients form ICs through the interaction of anti-CCP with citrullinated autoantigens10. Although we did not explore this in detail here, our results agree with this because t-SNE analysis suggests that some EV-CPs+also were IgG+ and IgM+, mainly in seropositive patients.
In concordance with our study, other groups have demonstrated an increase in intermediate monocytes in the circulation of patients with RA35. Interestingly, we also found this increase was present mainly in the circulation and SF of seropositive patients and that EV-ICs were mostly captured by intermediate monocytes of RA patients compared with cells of HCs. Other monocyte subsets have been studied in seropositive patients with RA. In a recent study, two populations of circulating monocytes were evaluated48. M1 monocytes were defined as positive for CD14, CD68, and CCR2, whereas M2 monocytes were defined as positive for CD14, CX3CR1, and CD163. The authors demonstrated that patients with RA positive for ACPA had higher M1/M2 ratios. Moreover, a positive correlation was observed between the M1/M2 ratio and the number of differentiated osteoclast detected in vitro in samples of patients with RA. Furthermore, M1 monocytes produced higher concentrations of IL-6 upon stimulation with lipopolysaccharide than M2 monocytes. However, because the expression of CD16 was not studied in M1 and M2 monocytes, it is not possible at this point to compare these data with our results.
Previously, CD16+ monocytes found in the SF of RA patients have been associated with elevated levels of proinflammatory cytokines and joint destruction17,49, and RA patients have shown a negative correlation between intermediate monocyte frequency and disease activity scores; however, in our study we did not find this association (Figure S2 and data not shown), instead, we found that alterations in intermediate monocytes and EVs, along with the elevated serum concentrations of IL-6, TNF-α, and IL-1β, were closely related in seropositive patients. Actually, intermediate monocytes exhibited more remarkable phenotypic changes in the SF of seropositive patients with RA than those observed in the peripheral blood of the same patients. This suggests that intermediate monocytes in the joint have a more significant involvement than their blood counterparts, which can be related to proinflammatory activation or differentiation of these cells once they reach this location50. Additionally, EVs induced the secretion of IL1β, IL6, and TNF-α by mononuclear phagocytes. Previously, it has been proposed that the targeting of monocytes/macrophages should be a powerful way of inhibiting inflammation and bone erosion in RA35. Considering all of these aspects, it is tempting to speculate that the suppression of monocyte subsets, mainly intermediate ones (for example, by avoiding their interaction with EVs), may ameliorate the systemic inflammatory process observed in patients with seropositive RA. Actually, the anti-TNF-α (inflixamab, adalimumab, etanercept, among others) and anti-IL-6 (tocilizumab, sarilumab, sirukumab, among others) biological therapies, which are effective RA treatments51,52, may be partially useful by targeting monocyte proinflammatory responses to circulating EVs. Given that, in the present study, biological therapy was a variable of exclusion, further investigations are required to identify whether seropositive patients with RA under anti-TNF-α and anti-IL-6 treatments have fewer EVs and monocytes alterations, possibly related with less systemic inflammation. However, it is important to mention that the treatment received by the patients of this study was not related to the alterations observed in EVs and monocyte subsets (Data not shown).
Finally, our results in part explain the systemic inflammatory phenomenon that is occurring in patients with seropositive RA in which EVs and monocyte subsets appear to contribute. Seropositive patients are characterized by an increased number of intermediate monocytes and the presence of EV-ICs+ and EV-CPs+ together with the proinflammatory cytokines IL-1β, IL-6, and TNF-α. Therefore, the measurement of these circulating components could be a useful approach for establishing parameters of systemic inflammation in patients with RA that are not evaluated in any way by conventional tools, such as the DAS28.
Reagents, materials, and antibodies
RPMI-1640 medium supplemented with GlutaMAX, Dulbecco’s phosphate-buffered saline (DPBS) and fetal bovine serum (FBS) were purchased from Gibco-BRL (Grand Island, NY). Paraformaldehyde was acquired from Thermo Fisher Scientific, Inc. (Pittsburgh, PA). Histopaque®−1077, trypan blue, penicillin, and streptomycin were purchased from Cambrex-BioWhittaker (Walkersville, MD). Annexin-V, Annexin-V binding buffer, Lysing Solution, the BDTM Human Inflammatory Cytometric Bead Array (CBA), and BD FACSFlowTM were purchased from BD Pharmingen (San Diego, CA). Sterile polystyrene 12 × 75-mm tubes were acquired from BD Falcon (San Diego, CA). Absolute counting beads were obtained from Beckman Coulter (Hialeah, FL). A Fluoresbrite Calibration Grade Size Range Kit (YG calibration grade spheres with diameters of 0.5 μm, 1.0 μm, 2.0 μm, 3.0 μm, and 6.0 μm), Fluoresbrite YG Microspheres (0.1 μm), and Fluoresbrite YG Microspheres (0.2 μm) were acquired from Polysciences, Inc. (Warrington, PA). Rosette Sep Human Monocyte Enrichment Cocktail was obtained from STEMCELL Technologies (British Columbia, Vancouver, Canada).
Monoclonal anti-human MY4 (CD14)-FITC (Clone 322A-1) and MY4-RD1 (Clone 322A-1) were obtained from Beckman Coulter; the antibodies against human CD16-V450 (Clone 3G8), CD32-PE (Clone 3D3), CD36-APC (Clone CD38, also known as NL07), CD11b-PE (Clone D12), CD18-APC (Clone 6.7), FcμR-Alexa Fluor 647 (Clone HM14–1), CD41a-PE (Clone HIP8), CD3-PE (Clone 17A1), CD33-PB (Clone WM53), CD105-BV421 (Clone 266), CD19-V450 (Clone HIB19), CCR2-Alexa Fluor 647 (Clone 48607), and CD45-PE-Cy7 (Clone HI30) were acquired from BD Biosciences (San Diego, CA). Monoclonal anti-human CX3CR1-PE (Clone 2A9-1), CCR5-PE-Cy7 (Clone J418F1), HLA-DR-APC-Cy7 (Clone L243), were obtained from BioLegend (San Diego, CA). Monoclonal anti-human C1q-FITC (Clone ab4223), citrulline-primary antibody (Clone ab100932), and anti-rabbit IgG H&L-Alexa Fluor 647-secondary antibody (Clone ab150079) were obtained from Abcam (San Francisco, CA). The antibody against human HMGB1-APC (Clone 115603) from R&D Systems (Minneapolis, MN). The F(ab’)2 anti-IgG fragment conjugated with Alexa Fluor 488 and F(ab’)2 anti-IgM fragment conjugated with Alexa Fluor 647 were purchased from Jackson ImmunoResearch (Baltimore Pike, West Grove, PA). Anti-human CD235a-APC (Clone HIR2) was bought from eBioscience (San Diego, CA).
Patients and controls
Sixty patients with RA, diagnosed according to the American College of Rheumatology criteria and European League Against Rheumatism criteria2, were recruited at the Rheumatology Service of the Hospital Universitario San Vicente Fundación (HUSVF, Medellin-Colombia); their median age was 55 years with a range of 30 to 77 years, and 84% were women. The patients were clustered in three groups: one seronegative [anti-CCP−RF−, (n = 6)] and two seropositive [anti-CCP+RF+/− (n = 26) and anti-CCPhiRFhi (n = 28)]; none of the patients received biological therapy. As controls, we included 40 HCs with a median age of 46 years with a range of 25 to 77 years, and 85% were women; and 60 SLE patients with a median age of 46 with a range of 25 to 77 years, and 85% were women, only for measurement of serum cytokines19. Our study was carried out in accordance with the Declaration of Helsinki. Research protocol and informed consent were approved by the Universidad de Antioquia’s Medical Research Institute and HUSVF Ethics Committees. All the experiments were performed in compliance with good clinical practice and good laboratory practice, in accordance with relevant guidelines and regulations of Universidad de Antioquia’s Medical Research Institute. All patients and HCs provided signed informed consent.
Cytokines, autoantibodies, and CRP determination
To determine the serum cytokines IL-8, IL-6, IL-10, TNF-α, IL-1β, and IL12p70, the BDTM Human Inflammatory CBA was used according to the manufacturer’s instructions.
IgM and IgG RF, as well as the IgG anti-CCP, were determined in the serum of patients by commercial ELISA (Quanta-Lite RF-IgM, Quanta-Lite RF-IgG and Quanta-Lite CCP3-IgG; Innova Diagnostics, San Diego, CA) according to the manufacturer’s instructions. A positive result for RF was >20 IU/mL and for anti-CCP was >10 IU/mL according to the commercial house. Results between 10 and <250 IU/mL and ≥250 IU/mL for these antibodies were arbitrarily considered for the definition of the anti-CCP+RF+/− and anti-CCPhiRFhi groups, respectively.
CRP quantification was performed by immunoturbimetry using the commercial kit Reagent Dimension Flex Quantitative Determination CRP Extended Range and the Dimension Clinical Chemistry Systems (both from McKesson, San Francisco, CA).
Monocyte subset classification
The monocyte subsets were defined from total blood and SF by flow cytometry as we previously reported19,53: CD14++CD16− (classical), CD14++CD16+ (intermediate), and CD14 + CD16 ++ (non-classical) monocytes. Briefly, total blood was stained with anti-human CD45, CD14, CD16, and HLA-DR antibodies for 20 min at room temperature in darkness; fluorescence minus one (FMO) controls were performed for each antibody, and 100,000 cells were acquired immediately on the FACS CantoTM II flow cytometer by using the FACS DIVA software (BD).
Monocyte subsets immunophenotyping
Mononuclear cells from blood and SF were obtained by using a Ficoll density gradient as we previously described19. The expression of each molecule was evaluated by using specific antibodies against CCR2, CX3CR1, CD64, CD36, CD86, CD11b, CD32, FcμR, CD18, and HLA-DR on monocyte subsets (basic panel CD14, CD16, and HLA-DR). FMO controls were performed for each antibody by using the basic panel. Cells were blocked (DPBS plus 1% bovine serum albumin (BSA), 0.01% NaN3, and 10% inactivated FBS) and stained for 30 min at 4 °C, followed by two washes with washing buffer (DPBS plus 1% BSA and 0.01% NaN3). Immediately, 50,000 monocytes were acquired by flow cytometry.
Circulating and SF EVs were isolated and characterized as we previously described19 by using monoclonal antibodies against human CD41a-PE, CD45-PE-Cy7, CD105-BV421, CD33-PE, CD235a-APC, CD3-PE, CD19-V450, CD14FITC, CD16-BV450, HMGB1-APC, C1q-FITC, and HLA-DR-APC-Cy7. To measure EV-ICs, F(ab’)2 anti-IgG-Alexa Fluor-488 and anti-IgM-Alexa Fluor-647 fragments were used. To evaluate the presence of citrullinated peptides on EVs by flow cytometry, a specific primary antibody (rabbit polyclonal anti-human citrulline peptides antibody), and Alexa Fluor 647-labeled secondary antibody (anti-rabbit IgG H&L-Alexa Fluor 647-secondary antibody) were used. The EV size and count were evaluated with reference beads as we previously described19. Some EVs samples from patients with RA and HCs were evaluated through scanning transmission electron microscopy (STEM). For this purpose, the vesicles were fixed with 2.5% glutaraldehyde, deposited on copper-coated carbon STEM grids; dried in the grid at 40 °C, and contrasted with uranyl acetate and lead citrate. Finally, the samples were dried at room temperature and evaluated in the Tecnai G2 F20 microscope (FEI company, Hillsboro, OR). Images were recorded with an Ultra Scan 1000XP-P camera (Gatan, Inc, Pleasanton, CA).
EVs from plasma poor-platelets of eight patients with seropositive RA were obtained and frozen until use. For opsonization, approximately 1 × 106 EVs were mixed and incubated with 15 µg/mL purified IgG (isolated from plasma of 16 RA seropositive patients by affinity chromatography) for 60 min at 37 °C. The unbound antibodies were washed away with 1 mL of DPBS at 17,000 g for 60 min. The EV- formation was assessed by flow cytometry (Figure S3).
Monocyte isolation for culture with EVs and EV-ICs
Circulating monocytes were enriched by Rosette Sep, according to the manufacturer’s instructions. The purity of the CD14+ monocytes in all cases was greater than 90%. The binding and uptake of EVs and EV-ICs stained with 2 μM CFSE by monocyte subsets and phagocytes after 24 h of culture were performed at a ratio of 1:3 (cell: EVs) as reported19. To estimate the mean fluorescence intensity (MFI) of cells that internalized EVs, the samples were acquired on a flow cytometer in the presence or absence of 0.01% v/v trypan blue to quench the green fluorescence of surface-bound EVs.
Approximately 1.2 × 105 monocytes were cultured as we previously described54. Briefly, the cells were adhered in RPMI-1640-GlutaMAX with 0.5% inactivated autologous serum-depleted of EVs (iSA-f)19. Then, the cells were incubated in RPMI-1640 with 10% iSA-f in the presence or absence of EVs and EV-ICs for 120 hours. The supernatants were collected and frozen at −20 °C until cytokine assessment by CBA.
Comparisons among the RA groups’ patients and HCs were performed by Kruskal–Wallis test and Dunn’s post-hoc test (data as median ± interquartile range). Comparisons of more than one variable were performed by using ANOVA-II and Bonferroni post-hoc test (data as mean ± standard deviation). Statistical significance was set at p ≤ 0.05; *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, and ****p ≤ 0.0001. Correlations were made by determining the Spearman’s rank coefficient with a 95% confidence interval. To illustrate the variations in size and content of EVs, t-SNE analysis was applied, with perplexity set to 100, and down sampling to 50,000; t-SNE plots were colored according to the expression of chosen channels by using ACCENSE 0.0.5-beta software55. The gating analyses, cells/EV frequencies, and MFI were estimated by using FlowJo 10.2 software. The statistical analysis was performed by using GraphPad Prism version 7.2 (GraphPad Soft-ware Inc., San Diego, CA). Multivariate discriminant analysis and PCA were performed by using Statgraphics X64 Centurion XVI (Statpoint Technologies, Warrenton, VA, USA).
The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
McInnes, I. B. S. G. The pathogenesis of rheumatoid arthritis. N. Engl. J. Med. 365, 2205–2219 (2011).
Aletaha, D. et al. Rheumatoid arthritis classifi cation criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann. Rheum. Dis. 1580–1588, https://doi.org/10.1136/ard.2010.138461 (2010).
Gómez-Puerta, J. A. et al. Differences in synovial fluid cytokine levels but not in synovial tissue cell infiltrate between anti-citrullinated peptide/protein antibody-positive and -negative rheumatoid arthritis patients. Arthritis Res. Ther. 15 (2013).
Conigliaro, P. et al. Autoantibodies in inflammatory arthritis. Autoimmun. Rev. 15, 673–683 (2016).
Szekanecz, Z. & Koch, A. Macrophages and their products in rheumatoid arthritis. Current opinion in rheumatology 19 (2007).
Hennigan, S. & Kavanaugh, A. Interleukin-6 inhibitors in the treatment of rheumatoid arthritis. Ther. Clin. Risk Manag. 4, 767–775 (2008).
Toussirot, E. & Wendling, D. The use of TNF-alpha blocking agents in rheumatoid arthritis: an update. Expert Opin. Pharmacother. 8, 2089–2107 (2007).
Edalat, F. NIH Public Access. 40, 1301–1315 (2012).
Boilard, E. et al. Platelets amplify inflammation in arthritis via collagen-dependent microparticle production. Science 327, 580–3 (2010).
Cloutier, N. et al. The exposure of autoantigens by microparticles underlies the formation of potent inflammatory components: The microparticle-associated immune complexes. EMBO Mol. Med. 5, 235–249 (2013).
Malda, J., Boere, J., van de Lest, C. H. A., van Weeren, P. R. & Wauben, M. H. M. Extracellular vesicles - new tool for joint repair and regeneration. Nature reviews. Rheumatology 12, 243–249 (2016).
Burbano, C., Rojas, M., Vásquez, G. & Castaño, D. Microparticles That Form Immune Complexes as Modulatory Structures in Autoimmune Responses. Mediators Inflamm. 2015 (2015).
Stuhlmüller, B. et al. Identification of known and novel genes in activated monocytes from patients with rheumatoid arthritis. Arthritis Rheum. 43, 775–790 (2000).
Liote, F., Boval-Boizard, B., Weill, D., Kuntz, D. & Wautier, J. L. Blood monocyte activation in rheumatoid arthritis: increased monocyte adhesiveness, integrin expression, and cytokine release. Clin. Exp. Immunol. 106, 13–19 (1996).
Torsteinsdottir, I., Arvidson, N. G., Hallgren, R. & Hakansson, L. Monocyte activation in rheumatoid arthritis (RA): increased integrin, Fc gamma and complement receptor expression and the effect of glucocorticoids. Clin. Exp. Immunol. 115, 554–560 (1999).
Burmester, G. R. et al. The tissue architecture of synovial membranes in inflammatory and non-inflammatory joint diseases. I. The localization of the major synovial cell populations as detected by monoclonal reagents directed towards Ia and monocyte-macrophage antigens. Rheumatol. Int. 3, 173–181 (1983).
Kinne, R. W., Stuhlmuller, B. & Burmester, G.-R. Cells of the synovium in rheumatoid arthritis. Macrophages. Arthritis Res. Ther. 9, 224 (2007).
Nielsen, C. T. et al. Increased IgG on cell-derived plasma microparticles in systemic lupus erythematosus is associated with autoantibodies and complement activation. Arthritis Rheum. 64, 1227–1236 (2012).
Burbano, C. et al. Potential involvement of platelet-derived microparticles and microparticles forming immune complexes during monocyte activation in patients with systemic lupus erythematosus. Front. Immunol. 9, (2018).
Rossol, M., Kraus, S., Pierer, M., Baerwald, C. & Wagner, U. The CD14 brightCD16+ monocyte subset is expanded in rheumatoid arthritis and promotes expansion of the Th17 cell population. Arthritis Rheum. 64, 671–677 (2012).
Withrow, J. et al. Extracellular vesicles in the pathogenesis of rheumatoid arthritis and osteoarthritis. Arthritis Res. Ther. 18, 286 (2016).
Pisetsky, D. S., Ullal, A. J., Gauley, J. & Ning, T. C. Microparticles as mediators and biomarkers of rheumatic disease. Rheumatol. (United Kingdom) 51, 1737–1746 (2012).
Shi, C. & Pamer, E. G. Monocyte recruitment during infection and inflammation. Nat. Rev. Immunol. 11, 762–774 (2011).
Scrivo, R. et al. Distribution of interleukin-10 family cytokines in serum and synovial fluid of patients with inflammatory arthritis reveals different contribution to systemic and joint inflammation. Clin. Exp. Immunol. 179, 300–308 (2015).
Sattar, N., McCarey, D. W., Capell, H. & McInnes, I. B. Explaining How ‘High-Grade’ Systemic Inflammation Accelerates Vascular Risk in Rheumatoid Arthritis. Circulation 108, 2957–2963 (2003).
Ohmura, K. et al. Anti-citrullinated peptide antibody-negative RA is a genetically distinct subset: a definitive study using only bone-erosive ACPA-negative rheumatoid arthritis. Rheumatology (Oxford). 49, 2298–2304 (2010).
van der Woude, D. et al. The ACPA isotype profile reflects long-term radiographic progression in rheumatoid arthritis. Ann. Rheum. Dis. 69, 1110–1116 (2010).
González-Álvaro, I. et al. Interleukin 15 levels in serum may predict a severe disease course in patients with early arthritis. PLoS One 6, 1–9 (2011).
MU, R. et al. Elevated Serum Interleukin 33 Is Associated with Autoantibody Production in Patients with Rheumatoid Arthritis. J. Rheumatol. 37, 2006–2013 (2010).
Gorlino, C. V. et al. Association between levels of synovial anti-citrullinated peptide antibodies and neutrophil response in patients with rheumatoid arthritis. Eur. J. Immunol. 1563–1572, https://doi.org/10.1002/eji.201847477 (2018).
Krishnamurthy, A. et al. Identification of a novel chemokine-dependent molecular mechanism underlying Rheumatoid arthritisassociated autoantibody-mediated bone loss. Ann. Rheum. Dis. 75, 721–729 (2016).
Wigerblad, G. et al. Autoantibodies to citrullinated proteins induce joint pain independent of inflammation via a chemokine-dependent mechanism. Ann. Rheum. Dis. 75, 730–738 (2016).
Catrina, A. I., Svensson, C. I., Malmstrom, V., Schett, G. & Klareskog, L. Mechanisms leading from systemic autoimmunity to joint-specific disease in rheumatoid arthritis. Nat. Rev. Rheumatol. 13, 79–86 (2017).
White, F. A., Jung, H. & Miller, R. J. Chemokines and the pathophysiology of neuropathic pain. Proc. Natl. Acad. Sci. 104, 20151–20158 (2007).
Davignon, J.-L. et al. Targeting monocytes/macrophages in the treatment of rheumatoid arthritis. Rheumatology (Oxford). 52, 590–598 (2013).
McInnes, I. B. Rheumatoid arthritis. From bench to bedside. Rheum. Dis. Clin. North Am. 27, 373–387 (2001).
Baron, M., Boulanger, C. M., Staels, B. & Tailleux, A. Cell-derived microparticles in atherosclerosis: biomarkers and targets for pharmacological modulation? J. Cell. Mol. Med. 16, 1365–1376 (2012).
del Rincon, I. D., Williams, K., Stern, M. P., Freeman, G. L. & Escalante, A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum. 44, 2737–2745 (2001).
Kirkland, T. N. & Viriyakosol, S. Structure-function analysis of soluble and membrane-bound CD14. Prog. Clin. Biol. Res. 397, 79–87 (1998).
Bazil, V. & Strominger, J. L. Shedding as a mechanism of down-modulation of CD14 on stimulated human monocytes. J. Immunol. 147, 1567–1574 (1991).
Mikuls, T. R. et al. Soluble CD14 and CD14 polymorphisms in rheumatoid arthritis. J. Rheumatol. 38, 2509–2516 (2011).
Boshkov, L. K., Kelton, J. G. & Halloran, P. F. HLA-DR expression by platelets in acute idiopathic thrombocytopenic purpura. Br. J. Haematol. 81, 552–557 (1992).
Semple, J. W. et al. Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura: relationship to platelet phenotype and antiplatelet T-cell reactivity. Blood 87, 4245–4254 (1996).
Gyorgy, B. et al. Improved flow cytometric assessment reveals distinct microvesicle (cell-derived microparticle) signatures in joint diseases. PLoS One 7, e49726 (2012).
Mustonen, A.-M. et al. First in vivo detection and characterization of hyaluronan-coated extracellular vesicles in human synovial fluid. J. Orthop. Res. 34, 1960–1968 (2016).
Khlebtsov, B. N., Burygin, G. L., Matora, L. Y., Shchyogolev, S. Y. & Khlebtsov, N. G. A method for studying insoluble immune complexes. Biochim. Biophys. Acta 1670, 199–207 (2004).
Schattner, M. et al. Activation of human platelets by immune complexes prepared with cationized human IgG. Blood 82, 3045–3051 (1993).
Iwamoto, N. M1 and M2 Monocytes in rheumatoid arthritis: a contribution of imbalance of M1/M2 Monocytes to Osteoclastogenesis. 8, 1–10 (2018).
Iguchi, T., Kurosaka, M. & Ziff, M. Electron microscopic study of HLA-DR and monocyte/macrophage staining cells in the rheumatoid synovial membrane. Arthritis Rheum. 29, 600–613 (1986).
Wynn, T. A., Chawla, A. & Pollard, J. W. Macrophage biology in development, homeostasis and disease. Nature 496, 445–455 (2013).
Md Yusof, M. Y. & Emery, P. Targeting interleukin-6 in rheumatoid arthritis. Drugs 73, 341–356 (2013).
Neovius, M. et al. Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab. Ann. Rheum. Dis. 74, 354–360 (2015).
Burbano, C., Vasquez, G. & Rojas, M. Modulatory effects of CD14+CD16++ monocytes on CD14++CD16− monocytes: a possible explanation of monocyte alterations in systemic lupus erythematosus. Arthritis Rheumatol. (Hoboken, N.J.) 66, 3371–3381 (2014).
Castaño, D., García, L. F. & Rojas, M. Increased frequency and cell death of CD16+monocytes with Mycobacterium tuberculosis infection. Tuberculosis 91, 348–360 (2011).
Shekhar, K., Brodin, P., Davis, M. M. & Chakraborty, A. K. Automatic Classification of Cellular Expression by Nonlinear Stochastic Embedding (ACCENSE). Proc. Natl. Acad. Sci. 111, 202–207 (2014).
C. Burbano is a recipient of a doctoral scholarship from COLCIENCIAS (call 617-2013). The authors are grateful for grants from “Sostenibilidad and Sistema Universitario de Investigaciones, CODI” (2013-05-42869836) from Universidad de Antioquia, and the COLCIENCIAS project (111565740575). The authors thank Blanca Ortiz for helping in the ELISA process, Janine Orejuela for her support in gathering the clinical data, and Natalia Ortiz and Johana Arboleda (Transmission Electron Microscopy Facility, Universidad de Antioquia) for helping with STEM procedure.
Electronic supplementary material
About this article
Endothelial activation and injury by microparticles in patients with systemic lupus erythematosus and rheumatoid arthritis
Arthritis Research & Therapy (2019)